Senior Network Engineer

Industry-First fully digital single-pass UV solution advances high-speed print production from Barberan and Fujifilm. Barberan and Fujifilm have unveiled the next milestone in their strategic single-pass technology partnership, introducing a fully digital print solution to the Nautilus system, complete with an integrated digital varnish capability. The latest development was previewed during a successful open day held at Barberan in May 2026, marking another step forward in redefining the possibilities of high-speed inkjet production. 07.08.2026 Single-pass productivity has long been embedded in Barberan's DNA, with the company leading the market in corrugated printing where quality and throughput go hand in hand. However, bringing single-pass technology into the graphics market presented two significant challenges: supporting shorter production runs across a much broader range of media, and overcoming the high-gloss finish traditionally associated with single-pass UV printing. Conventional solutions rely on analogue primers and matt varnishes, adding complexity, longer make-ready times and increased consumable costs. More importantly, these approaches can limit the ability to print onto thinner and more flexible substrates such as paper. For Barberan and Fujifilm, two businesses driven by innovation, the answer needed to be entirely digital. Working closely together, the chemistry specialists at Fujifilm Ink, based in Broadstairs, UK, developed a new suite of UV inks engineered to deliver exceptional print quality and broad substrate adhesion, reducing and in many cases eliminating the need for analogue primers. The result is a significant advancement in ink technology, extending media flexibility and enabling printing onto thinner papers than many existing single-pass platforms can currently achieve. The next challenge centred on surface finish. While digital varnishes are well established within multi-pass applications, adapting this expertise for single-pass production required a new level of technical precision. Through close collaboration with customers and a clear understanding of market requirements, Fujifilm Ink successfully developed a fully integrated digital varnish solution for single-pass UV printing, which boasts a satin finish. The technology was demonstrated publicly at FESPA 2026 in Barcelona through a number of printed displays and subsequently showcased to prospective customers during a dedicated open house event at Barberan. One market set to benefit significantly is out-of-home advertising, where increasing demand for localised and targeted campaigns is driving the need for flexible, high-productivity print solutions. Where a fully digital infrastructure is not available, traditional alternatives often rely on slower multi-pass systems or printing with an analogue process. The Nautilus single-pass platform changes this dynamic, delivering more than 1,400 high-quality 2050 x 1600 mm sheets per hour, with every sheet capable of carrying unique content. Combined with Barberan's innovative alignment conveyor technology, duplex printing can be achieved with registration accuracy of +/-0.1 mm.

Supplier news: Piramal, Codis, Fujifilm bio & more. The latest from cdmos, cmos, and suppliers featuring Piramal Pharma Solutions, Codis, Fujifilm Biotechnologies, nuecell bio and Altasciences. Chemicals/Chemical API Manufacturing Piramal Pharma Adds Spray-Drying Suite in Peptide API Facility Piramal Pharma Solutions, a CDMO of active pharmaceutical ingredients and drug products, has added a spray-drying suite at its dedicated peptide development and manufacturing facility in Turbhe, India, to enable the formulation of challenging molecules, including peptides, high-potency active pharmaceutical ingredients, and other biomolecules. The new spray-drying suite operates as a closed-loop system, equipped with its own inert gas supply and advanced safety measures, including specialized HVAC, airlocked entries and exits, operator isolation, and a dedicated cleaning area to enable the safe handling of potent compounds and organic solvents requiring up to Band 5 containment. To further strengthen these capabilities, the processing area maintains ISO Class 8 (Class 100,000) standards. Biologics Manufacturing NueCell-Bio Launches as Cell Therapy CDMO NueCell Bio has launced as a new CDMO of cell therapies. NueCell Bio is headquartered in the Sorrento Valley area of San Diego in a 26,300-square-foot-facility that specializes in translational services for cell therapies. Formulation Development/Drug Product Manufacturing Codis Completes Acquisition of Catalent Spray-Drying Facility Codis, a contract provider specializing in commercial-scale spray drying, amorphous solid dispersions, and particle-engineering technologies, has completed its acquisition of the Nottingham, UK, facility of Catalent Pharma Solutions. The facility provides oral solid dose development and small-scale manufacturing capabilities. The facility will complement Codis' large-scale commercial spray-drying facility in Haverhill, UK, which is now undergoing expansion with a new GEA Pharma-SD type PSD-4 commercial spray dryer scheduled to be validated in 2027. Altascience Expands Drug Product R&D Lab Altasciences, a Laval, Quebec, Canada-based CDMO, has expanded the R&D laboratory at its drug-product formulation and manufacturing services facility in Harleysville, Pennsylvania, adding approximately 768 square feet of new laboratory space. The enhanced laboratory supports phase-appropriate, target product profile-driven formulation screening. Capabilities include formulation development for small molecules, peptides, and complex modalities, as well as non-GLP and GLP toxicology samples for nonclinical studies. Appointments Fujifilm Biotechnologies Names New CEO in Planned Succession Fujifilm Biotechnologies has appointed Maja Pedersen, currently Chief Operating Officer of the company, to President, in addition to her role as Chief Operating Officer, effective immediately (as reported on August 4, 2026). The appointment is part of a planned leadership succession with Lars Petersen, formerly President and CEO of the company, who is transitioning his role to a Strategic Advisor, through September 30, 2026. Maja Pedersen was appointed to Chief Operating Officer in 2025, and in that role, she is responsible for site operations, supply chain, quality, process development, and global manufacturing science and technology. Before that, she was the company's Chief Quality Officer, overseeing the organization's global quality network across multiple manufacturing sites and responsible for institutionalizing global quality standards and creating a streamlined global regulatory process. Prior to that, she was Global Head of External Manufacturing at Biogen, where she oversaw the company's CDMO network. She has over 20 years of leadership experience in life sciences and bio/pharma, holding senior leadership positions in quality assurance and control, regulatory affairs, and external manufacturing.

Fujifilm announces financial results for the first quarter ended June 30, 2026. TOKYO, August 6, 2026 - FUJIFILM Holdings Corporation announced today its financial results for the first quarter, which ended June 30, 2026. First quarter results for the fiscal year ended June 30, 2026. * Revenue was JPY826.5 billion and increased 10.3% year-over-year. * Operating income was JPY51.2 billion and decreased 32.0% year-over-year, broadly in line with the internal plan. * Net income attributable to FUJIFILM Holdings was JPY37.4 billion and decreased 30.4% year-over-year. Outlook for fiscal year ending March 2027. * For the fiscal year ending March 2027, the company projects record-high financial performance, with revenue of JPY3.56 trillion, reflecting strong sales in the Electronics segment and favorable foreign exchange impacts. * Operating income is expected to reach JPY365.0 billion, in line with the previous forecast, as increased profits in the Electronics segment are expected to be offset by delays in the ramp-up of Bio CDMO facilities and the impact of rising semiconductor memory prices. * Net income attributable to FUJIFILM Holdings is forecasted at JPY280.0 billion. Revenue increased to a record high, driven by strong performance particularly in semiconductor materials and data tapes in the Electronic segment. While increased costs in Bio CDMO, one-time expenses related to strengthening the operational foundation of the Business Innovation, and higher raw material prices created headwinds for profitability, the Company revised its revenue forecast upward from the previous outlook, reflecting strong business performance. "While reported operating income was affected by higher costs and one-time expenses, underlying performance remained broadly in line with our expectations. Supported by the strength of our growth businesses and continued expansion of demand, we have revised our revenue forecast upward and remain confident in our long-term growth trajectory," says Teiichi Goto, president and chief executive officer, representative director, FUJIFILM Holdings Corporation. First quarter financial highlights from April to June by business segments. Healthcare. * Revenue increased by 12.4% year-over-year to JPY256.8 billion, while operating income declined to a loss of JPY12.7 billion, primarily due to the increased cost in Bio CDMO and higher raw material costs due to surging silver prices. * In the Medical Systems business, the company maintained strong growth, supported by increased sales in Japan and China in addition to major markets such as the United States and Europe. Higher sales of Healthcare IT solutions also contributed to revenue growth. * In the Bio CDMO business, revenue grew by more than 6%, driven by the ramp-up of new large-scale facilities and the absence of the planned facility shutdowns that occurred in the previous fiscal year. In contrast, revenue from small- and medium-scale facilities declined due to unplanned shutdowns associated with regulatory inspections and the absence of cancellation fees recorded in the previous fiscal year. * In the LS Solutions business, revenue increased, driven by expanded use of cell culture media among major pharmaceutical companies. Electronics. * Revenue increased by 25.0% year-over-year to JPY127.7 billion, and operating income rose by 38.2% year-over-year to JPY31.1 billion. * In the Electronic Materials business, revenue increased, supported by strong sales of the world's leading CMP slurries for copper interconnects and NTI developers, together with solid sales of liquid polyimides for advanced semiconductor packaging applications. * In the Advanced Functional Materials business, revenue increased, supported by higher sales of data tapes to major IT companies. Business Innovation. * Revenue decreased by 0.1% year-over-year to JPY273.2 billion, and operating income declined to a loss of JPY17.0 billion. * In the Business Solutions business, revenue increased, driven by higher sales in overseas enterprise system sales and implementation support services. * In the Office Solutions business, revenue declined due to lower exports to Europe and North America and reduced demand for equipment replacements in China. * In the Graphic Communications business, revenue increased due to strong sales of inkjet printheads. Imaging. * Revenue increased by 16.2% year-over-year to JPY168.8 billion, and operating income rose by 3.9% year-over-year to JPY43.4 billion. * In the Consumer Imaging business, revenue increased due to strong sales of instax(TM) products, supported by robust demand for mid- to high-end models such as the instax mini Evo(TM) and instax WIDE 400(TM), coupled with the successful launch of the new entry-level instax mini 13(TM), and increased supply following capacity expansion for instax(TM) film production. * In the Professional Imaging business, revenue increased, driven by strong sales of key models including the X-T30 III and X-E5, as well as continued strong demand for long-selling products such as the X100VI. For more details, please visit the Investor Relations section of Fujifilm website Contact. Media contact. FUJIFILM Holdings Corporation Corporate Communications Division, Public Relations Group * * Please note that the contents including the product availability, specification, prices and contacts in this website are current as of the date of the press announcement and may be subject to change without prior notice.